Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0L8OP
|
||||
| Former ID |
DIB015081
|
||||
| Drug Name |
AVP-21D9
|
||||
| Synonyms |
Thravixa; AVP-1C6; AVP-22G12; AVP-8C1; Anthrax antibody, AVANIR; Anthrax toxin Mab, Xenerex; Protective antigen-targeting human monoclonal antibodies (intravenous, anthrax), AVANIR; Protective antigen-targeting human monoclonal antibodies (intravenous, anthrax), Emergent
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Bacillus anthracis infection [ICD10:A22] | Phase 1 | [1] | ||
| Company |
Emergent biosolutions
|
||||
| Target and Pathway | |||||
| Target(s) | Protective antigen | Target Info | [2] | ||
| Pathway Interaction Database | Cellular roles of Anthrax toxin | ||||
| Reactome | Uptake and function of anthrax toxins | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01202695) Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9). U.S. National Institutes of Health. | ||||
| REF 2 | Efficacy and Safety of AVP-21D9, an Anthrax Monoclonal Antibody, in Animal Models and Humans. Antimicrob Agents Chemother. 2014 July; 58(7): 3618-3625. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.